Shots:
- Akeso has enrolled & dosed its first patient with cadonilimab (PD-1/CTLA-4 BsAb) + CT in P-III (AK104-310/COMPASSION-33) trial for the perioperative treatment of resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma
- The P-III (COMPASSION-33) trial in resectable G/GEJ adenocarcinoma pts is designed to improve radical resection rates, lower recurrence & metastasis risk, & improve patient outcomes
- Additionally, cadonilimab + pulocimab (VEGFR-2) is being investigated in an ongoing P-III trial as a 2L treatment of immune therapy (IO)-resistant advanced gastric cancer
Ref: PRNewswire | Image: Akeso |Press Release
Related News:- Akeso’s Cadonilimab Receives the NMPA’s Approval for 1L Treatment of Cervical Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
